Cara Therapeutics (CARA) Bullish Stance Reiterated at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Cara Therapeutics, Inc. (CARA) Posts Mixed Q4 Results
March 27, 2014 4:03 PM EDTCara Therapeutics, Inc. (NASDAQ: CARA) reported Q4 EPS of ($0.49), $0.31 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.52 million.
For earnings history and earnings-related data on (not found) (CARA) click here.... More



